Clinical trial NCT03444714: Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Official title: Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Tumors
Keywords: intratumoral
Lead sponsor: Coordination Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
Collaborators: name: University of Chicago
First posted: 2018-02-23
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: 3 + 3 dose escalation study design
Primary purpose: TREATMENT

Brief summary: This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes.

Condition or Disease:

Patient with advanced tumor which is clinically accessible for intratumoral injection

Intervention/Treatment:

Drug - RiMO-301

Radiation - Radiotherapy

Phase:

Phase 1

Detailed description: Primary Objectives:

• The primary objective is to determine the maximum tolerated dose (MTD) of RiMO-301 as determined by toxicity observed in patients treated with palliative radiation doses

Secondary Objectives:

* To determine clinical response after RiMO-301 and radiotherapy as assessed by clinical response rate using clinical evaluation, imaging and/or symptom relief
* To characterize adverse events of RiMO-301 in patients with advanced cancers
* To evaluate the pharmacokinetics (PK) of RiMO-301 with radiation

The target population is patients with clinically accessible lesions for intratumoral injection. Up to 3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study design. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intratumor injection of RiMO-301 to 30 days after the completion of radiation treatment:

* Grade 4 or greater treatment related hematologic or dermatologic toxicity
* Any Grade 3 or greater treatment related non-hematologic, non-dermatologic toxicity (excluding nausea, vomiting or diarrhea without maximal medical intervention)

Eligibility criteria: Inclusion Criteria:

* Diagnosis of advanced or metastatic cancer not amenable to curative therapy
* Lesion that is amenable to palliative radiotherapy
* Lesion that is technically feasible to irradiation and accessible for direct intratumoral injection
* Target tumor in region not in previously irradiated field
* Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment
* Age \>18 years
* Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion
* Females with child bearing age should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to the start of dosing
* Patients must sign a study-specific informed consent form prior to study entry

Exclusion Criteria:

* Patients with a histological diagnosis of lymphomas and/or leukemias
* Patients may not have received chemotherapy, targeted therapies, biologic response modifiers and/or hormonal therapy within the last 14 days
* Ongoing clinically significant infection at or near the incident lesion
* Major surgery over the target area (excluding placement of vascular access) \<21 days from beginning of the study drug or minor surgical procedures \<7 days
* Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
* Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
* Pregnant and nursing women
* Patients with a target lesion located in a previously irradiated field

Primary outcomes:
measure: Maximum Tolerated Dose (MTD)
timeFrame: 45 days
Secondary outcomes:
measure: clinical benefit
timeFrame: 45 days
measure: adverse effect
timeFrame: 45 days
measure: Maximum Plasma Concentration [Cmax]
timeFrame: 45 days
measure: Area Under the Curve [AUC]
timeFrame: 45 days
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago
state: Illinois
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
Study officials:
References: